We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+21.26%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$3.77B
AUM Growth
+$720M
(+24%)
Cap. Flow
+$280M
Cap. Flow
% of AUM
7.43%
Top 10 Holdings %
Top 10 Hldgs %
22.38%
Holding
294
New
116
Increased
45
Reduced
52
Closed
77
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$115M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$93.9M |
| 3 |
NXP Semiconductors
NXPI
|
+$57.1M |
| 4 |
Eli Lilly
LLY
|
+$51.1M |
| 5 |
Qorvo
QRVO
|
+$47.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$72.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$66.5M |
| 3 |
Amazon
AMZN
|
+$65.6M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$58.8M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$53.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.9% |
| 2 | Technology | 32.83% |
| 3 | Communication Services | 8.98% |
| 4 | Financials | 3.92% |
| 5 | Consumer Discretionary | 3.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Jabil
JBL
$33.4B
| $8.57M | 0.23% |
+201,415
| New | +$7.63M |
|
127
Zai Lab
ZLAB
$2.05B
| $8.31M | 0.22% |
+61,370
| New | +$6.25M |
|
|
BOWX
128
DELISTED
BowX Acquisition Corp. Class A Common Stock
BOWX
| $8.26M | 0.22% |
+805,161
| New | +$8.08M |
|
129
Outset Medical
OM
$92.5M
| $8.22M | 0.22% |
9,641
+1,269
| +15% | +$978K |
|
130
TripAdvisor
TRIP
$1.69B
| $8.06M | 0.21% |
280,000
-1,221,295
| -81% | -$29.4M |
|
131
Chewy
CHWY
$9.87B
| $7.81M | 0.21% |
+86,843
| New | +$6.33M |
|
132
Monster Beverage
MNST
$91.5B
| $7.45M | 0.2% |
+161,036
| New | +$6.77M |
|
133
Semtech
SMTC
$12B
| $7.43M | 0.2% |
+103,084
| New | +$6.58M |
|
134
PTC Therapeutics
PTCT
$5.68B
| $7.35M | 0.2% |
120,471
-172,139
| -59% | -$10.1M |
|
135
Airbnb
ABNB
$89B
| $7.34M | 0.19% |
+50,000
| New | +$7.38M |
|
136
Under Armour
UAA
$2.89B
| $7.33M | 0.19% |
+426,684
| New | +$6.52M |
|
137
New York Times
NYT
$12.2B
| $7.27M | 0.19% |
+140,472
| New | +$6.24M |
|
138
Zentalis Pharmaceuticals
ZNTL
$331M
| $7.27M | 0.19% |
140,000
+2,116
| +2% | +$95.4K |
|
139
Forte Biosciences
FBRX
$1.57B
| $7M | 0.19% |
+7,691
| New | +$7.23M |
|
|
DISH
140
DELISTED
DISH Network Corp.
DISH
| $6.99M | 0.19% |
+216,003
| New | +$6.65M |
|
141
Akebia Therapeutics
AKBA
$351M
| $6.67M | 0.18% |
2,382,522
-3,076,414
| -56% | -$8.98M |
|
142
Scholar Rock
SRRK
$5.49B
| $6.62M | 0.18% |
+136,458
| New | +$4.95M |
|
|
KRON
143
DELISTED
Kronos Bio
KRON
| $6.62M | 0.18% |
+221,487
| New | +$6.95M |
|
|
JNCE
144
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $6.59M | 0.17% |
940,902
+11,251
| +1% | +$87.6K |
|
145
Charles River Laboratories
CRL
$11.3B
| $6.55M | 0.17% |
+26,203
| New | +$6.24M |
|
146
Viatris
VTRS
$20.6B
| $6.49M | 0.17% |
+346,228
| New | +$5.65M |
|
147
Cue Biopharma
CUE
$113M
| $6.38M | 0.17% |
17,003
-13,486
| -44% | -$5.39M |
|
148
WEX
WEX
$6.45B
| $6.27M | 0.17% |
+30,816
| New | +$5.18M |
|
149
Tango Therapeutics
TNGX
$4.78B
| $5.76M | 0.15% |
503,397
+3,397
| +0.7% | +$35.8K |
|
|
BLSA
150
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $5.71M | 0.15% |
+512,616
| New | +$5.5M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q4 2020 Portfolio in Review
As of Q4 2020, Woodline Partners held 294 positions worth $3.77B, up 24% from $3.05B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Woodline Partners deployed $280M of net new capital in Q4 2020, opening 116 new positions and adding to 45 existing holdings. Its largest new stake was Amgen: 500,520 shares worth $115M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $58.8M trimmed.
- Woodline Partners's largest Q4 2020 buy was Amgen: 500,520 shares worth $115M.
- Woodline Partners added most to Eli Lilly in Q4 2020, an estimated $51.1M increase.
- Woodline Partners's biggest Q4 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $58.8M.
- Woodline Partners fully exited Microchip Technology in Q4 2020, selling an estimated $72.6M.
- Woodline Partners's ten largest holdings make up 22% of its $3.77B portfolio in Q4 2020.
- Woodline Partners opened 116 new positions and closed 77 in Q4 2020.
- Woodline Partners's portfolio value rose 24% quarter-over-quarter to $3.77B.
Based on Woodline Partners's 13F filing for Q4 2020, filed 16 Feb 2021.